Neulasta and Osteopenia - a phase IV clinical study of FDA data

Summary:

Osteopenia is reported as a side effect among people who take Neulasta (pegfilgrastim), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Zometa, and have Osteoporosis.

The phase IV clinical study analyzes which people have Osteopenia when taking Neulasta. It is created by eHealthMe based on reports of 92,148 people who have side effects when taking Neulasta from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Osteopenia?

Osteopenia (a condition where bone mineral density is lower than normal) is found to be associated with 1,442 drugs and 1,171 conditions by eHealthMe. Check the latest studies of Osteopenia.

On Jul, 21, 2026

92,148 people reported to have side effects when taking Neulasta.
Among them, 88 people (0.1%) have Osteopenia.

Among these 88 people:

How long have people been on Neulasta when they have Osteopenia? *

What is the gender of people who have Osteopenia when taking Neulasta? *

female: 70.11 %
male: 29.89 %

What is the age of people who have Osteopenia when taking Neulasta? *

What are other drugs people take besides Neulasta? *

What are other side effects people have besides Osteopenia? *

Pain: 77 people, 87.50%
Anaemia (lack of blood): 68 people, 77.27%
Abdominal Pain: 50 people, 56.82%
Depression: 49 people, 55.68%
Injury: 47 people, 53.41%
Stress And Anxiety: 44 people, 50.00%
Osteonecrosis Of Jaw (death of bone of jaw): 43 people, 48.86%
Constipation: 40 people, 45.45%
Spinal Osteoarthritis (joint cartilage loss in spine): 40 people, 45.45%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 39 people, 44.32%

What are the existing conditions these people have? *

High Blood Cholesterol: 12 people, 13.64%
Vitiligo (pigment is lost from areas of the skin): 12 people, 13.64%
Osteoporosis (bones weak and more likely to break): 12 people, 13.64%
Prostate Cancer: 11 people, 12.50%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 7 people, 7.95%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 7 people, 7.95%
Pain: 5 people, 5.68%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 5.68%
Metastases To Bone (cancer spreads to bone): 4 people, 4.55%
High Blood Pressure: 3 people, 3.41%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and have Osteopenia?

- Check whether Osteopenia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neulasta:

Neulasta (92,286 reports)

Osteopenia treatments and more:

Osteopenia (46,948 reports)

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteopenia:

Osteopenia (1,442 drugs)

Browse all the conditions that are associated with Osteopenia:

Osteopenia (1,171 conditions)

Related publications that referenced our studies

Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .
Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim (the active ingredients of Neulasta) and Neulasta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.